The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
| Factor | Score | Distribution | Value | Avg | Verdict |
|---|---|---|---|---|---|
Valuation | 51 | — | 20.1x | Near average | |
Growth | 19 | — | 5.6% | Below average | |
Quality | 17 | -40.1% | 7.6% | Below average | |
Safety | 73 | 0.2x | 0.4x | Above average | |
Capital Return | 20 | 0.00% | 2.19% | Below average | |
Momentum | — | — | — | No data | |
Sentiment | — | — | — | No data |
Vaxcyte, Inc. is a publicly traded stock representing ownership in the company, giving holders rights to dividends and voting.
You can buy Vaxcyte, Inc. shares through a licensed brokerage. Research the company's financials before investing.
Key metrics include Price-to-Earnings (P/E) ratio, Return on Equity (ROE), revenue growth, and net profit margin.
Dividend policies vary by company. Check the dividends section on the stock page for the payout history.
Risks include market volatility, sector-specific risks, regulatory changes, and company financial performance. Diversification helps reduce risk.
AI analysis from the earnings call, financials and news
This section combines price targets, revision history, analyst coverage changes, and an AI summary of what changed on the Street.
Vaxcyte stock shows a state of complete stability in analyst estimates over the past 30 days, with the average price target stabilizing at 89 dollars. Notably, there is a total lack of Dispersion among the seven analysts covering the stock, as the high, low, and average price targets coincide at the same value, reflecting a strong and unusual consensus on the expected fair value in the foreseeable future.
Ten ratios that matter, each compared against its sector median and average — so you can see whether a number is rich or cheap relative to peers in the same sector.